Antibody Drug Conjugate Market Research Report – Forecast to 2027

Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) - Forecast 2027

ID: MRFR/Pharma/0607-HCR | February 2021 | Region: Global | 140 pages

Antibody Drug Conjugate Market Overview 

The antibody drug conjugate market size is expected to grow by 19% by 2023. The antibody drug conjugate is a crucial biopharmaceutical therapy for cancer treatment. It is an effective treatment that can eliminate cancer cells. Also, it only harms the cancer cells without harming the healthy cells in the body. There are plenty of benefits of the antibody-drug conjugate.

Due to its exceptional benefits, it is a treatment gaining high popularity in many regions. Patient recovery from cancer is faster with the antibody-drug conjugate. There are two major types of antibody-drug conjugate. The monoclonal and linker are two popular antibody drugs in the market. The prevalence of cancer is the factor that raises the demand for antibody-drug conjugate.

An unhealthy lifestyle and poor eating habits lead to more cancer cells in the body. The antibody-drug conjugate can identify and destroy cancer cells. The efficiency and effective mechanism are better than other cancer treatments. Due to its benefits, awareness about the treatment is increasing on a large scale. Biotechnology companies have tremendous demand for antibody-drug conjugate. In the forecast period, the market value will reach a high rate due to these factors. Also, the antibody drug conjugate market overview show massive expansion rate.

Covid analysis 

The outbreak of covid 19 is bringing terrible effects on global markets. The slowdown in other medical treatments affects profitability. The health industry is more focused to treat the covid cases. Most of the hospitals and clinics were flooded with covid patients during the last year. Cancer research and treatments is delayed in the last few years. It is causing plenty of challenges to the antibody drug conjugate market.

There is a slowdown in the production of these drugs during a pandemic. Also, the number of cancer patients visiting hospitals has significantly reduced during this period. The research and programs related to cancer antibodies developments came to a halt during this period. However, the operations of the market are gradually resuming. The research and investment for the antibody conjugate market are rising in the upcoming years. Also, large scale research and production are expected to take place in the forecast period. 

Market dynamics 

  • Crucial market drivers 

Technological advancements are the crucial driver for this market. In recent years, the technological advancements in the healthcare sector are remarkable. It is a necessary development in the health sector to manage chronic diseases. As per the WHO reports, the ageing population will increase by 16% in the upcoming years. The number of individuals above 65 years of age is more prone to health complications. The cancer cases in aged people are higher than in the younger population.

 Due to the increasing type and cases of cancer, the need for technological advancements is high. Innovation in medical technology leads to better treatment. With the use of better technologies, it is possible to provide the best treatment with the antibody-drug conjugate. Further, the demand for the market increases with the effected launch of technologies in the medical sector.

Moreover, the preclinical sector is increasing the research of antibodies for cancer. The investments for this sector are high in the upcoming years. It will result in advanced drug launches for most cancers. With the high rate of technological advancements, all these profitable events will take place in the antibody drug conjugate market. The increased antibody drug conjugate services will lead to a high revenue rate. 

  • Market growth opportunities 

An increase in research and development will lead to antibody drug conjugate market growth opportunities. The research and development investments for the health sector are tremendous for the forecast period. It increases the therapy reset of antibody drugs. There are high chances for new drug discoveries in the market. The monoclonal antibodies segment is combined with chemical payloads. This combination leads to an effective immunotherapy arsenal for cancer. These positive developments will attract new end users to the market.

Due to high research, the collaboration of institutes and biopharmaceutical firms will grow in the upcoming years. The launch of new drugs through this collaboration is another actor leading to growth opportunities. Further, the key players are planning to increase their product range. The antibody drug conjugate market will witness innovations and new product launches in the forecast period. These growth opportunities will increase the overall profitability rate. 

  • The market restraints 

The stringent governmental rule is the major restraint in this market. The use of antibody-drug conjugate requires plenty of compliance. The compliance and governmental standards delay the adoption of antibody drugs. The delayed reimbursement for this treatment is another restraint in the market.

The health insurance policies in many countries do not cover the pre-treatment for cancer. The antibody-drug conjugate is a preclinical treatment. The reimbursement for it is less. The lack of reimbursements and stringent government policies are the restraining factors of the market. It is a restraint that can cause the decline of demand for the market. 

  • The market challenge 

The medical sector is advancing at a rapid pace. These advancements are causing plenty of developments in the cancer drug market. These developments may lead to better alternatives for the drug conjugate. Also, it can affect the overall demand of the antibody drug conjugate market in the forecast period.

 The introduction of better alternatives can hamper the growth of the market. Further, the high cost of the treatment is another challenge in the market. The high cost of the procedure reduces the adoption rate of the market. Also, the demand can diminish due to the high cost and better alternatives. 

  • Cumulative growth analysis 

The growth trend of the market is surging during the forecast period. The prevalence of chronic illnesses is raising the demand for the market. Further, the technological advancements in the medical industry are the crucial driver of this market. Technological advancement benefits the antibody drug conjugate market. The technologies enable better treatments and utilization.

The increasing investments in the health sector are providing more growth opportunities for the market. Innovation and progression will lead to market expansion. Increasing collaboration of the market with other institutions will bring positive impacts. However, stringent government rules are a restraining factor. Further, the high cost of the procedure is a major drawback for the market. 

  • Value chain analysis 

North America will dominate with maximum antibody drug conjugate market share. The presence of key players is the crucial reason for high market growth. The awareness about the antibody drug conjugate market is high in this region. It leads to plenty of demand and development possibilities for the market.

 The prevalence of cancer is creating an immense need in North America. Further, the rising R&D investments in this region will have a positive impact. There are fewer regulatory restrictions in this region for antibody-drug conjugates. Due to all these factors, North America will record the highest profitability rate. 

Segment overview 

By drug type 

  • Kadcyla 

  • Adcetris 

By mechanism 

  • HER 2 antibodies 

  • CD30 antibodies 

By application 

  • Breast cancer 

  • Lymphoma 

By product 

  • Linker 

  • Monoclonal antibodies 

By technology 

  • Immunogenic technology 

  • Immunomedics technology 

By geography 

  • Asia pacific 

  • Europe 

  • North America 

Competitive landscape 

The competition in the antibody drug conjugate market is rising in the forecast period. The entry of new players will lead to more competition. Also, Expansions, product launches and innovation are a crucial part of the competitive landscape. Research and development will happen at a massive scale during the forecast period. 

Regional analysis 

The antibody drug conjugate market is diversified into Asia Pacific, Europe and North America. North America holds more than 50% of shares during the forecast period. The new types of cancer cases are leading to the tremendous demand for antibody-drug conjugate. The focus of the region is on the prediagnosis drug. With rising R&D expenditure the market will witness plenty of new developments. The presence top antibody drug conjugate companies is advantageous to the market.

The US market provides complete approval for the antibody-drug conjugate. The Asia Pacific is expected to be the fastest-growing antibody drug conjugate market in the forecast period. After America, Asia pacific is the next largest region with high cancer cases. There is a variety of new cancer cases in this region. Due to this, cancer treatment options are expanding rapidly. There is high demand and profitability for antibody-drug conjugate in Asia pacific. 

The key players of the antibody drug conjugate market are 

  • ADC Therapeutics

    • Takeda Pharmaceutical Company Ltd.

    • GlaxoSmithKline Plc

    • Hoffmann-La Roche Ltd.

    • Daiichi Sankyo Company Ltd.

  • Pfizer, Inc.

  • Seagen, Inc.

    • Gilead Sciences, Inc.

    • Astellas Pharma

Recent developments 

  1. The top institutes of oncology are choosing antibody-drug conjugate therapies. The adoption of the drug conjugates provides more awareness for the market.  

  1. The Takeda pharmacy is partnering with top institutes. The Takeda and partnership firm will produce the therapies together. 

Report overview 

  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. 6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments

Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   19%
  Base Year   2017
  Forecast Period   2027
  Historical Data   2016
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Type, product, technology, application, and end-user
  Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
  Key Vendors   Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US)
  Key Market Opportunities   Research activities
  Key Market Drivers

  • Advancement in the medical technology
  • Obese population
  • Growing ageing population

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The antibody drug conjugate market is projected to grow at a CAGR of approximately 19% during the forecast period, 2017–2023.

    North America holds the largest share in the global antibody drug conjugate market followed by Europe and Asia Pacific, respectively.

    ImmunoGen, Inc. (US), Seattle Genetics (US), Roche Holding AG (Switzerland), Concortis Biotherapeutics (US), Genentech (US), Agensys, Inc. (US), Immunomedics (US), Antikor (UK), Pfizer Inc. (US), Millennium Pharmaceuticals (US), Celldex Therapeutics (US), AbbVie Inc. (US), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Progenics Pharmaceuticals (US), Synthon (US), Oxford BioTherapeutics (US), Mersana Therapeutics (US), and Heidelberg Pharma (Germany), are some of the major players operating in the global antibody drug conjugate market.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global antibody drug conjugate market adopt to gain a larger competitive advantage.